Single Maintenance and Reliever Therapy (SMART) Regimen for Management of Persistent Asthma

Abstract

heading For every 16 patients who took single maintenance and reliever therapy (SMART), 1 case of asthma exacerbation was prevented Benefits in NNT NNT of 12 for prevention of one asthma exacerbation with SMART, compared to same-dose inhaled corticosteroid alone (NNT of 9 compared to higher dose inhaled corticosteroids alone) NNT of 16 for prevention of one asthma exacerbation with SMART, compared to the same dose of inhaled corticosteroid combined with a long-acting beta-agonist (NNT 37 compared to higher dose inhaled corticosteroid combined with a long-acting beta-agonist)Benefits in percentages 8.1% lower risk of asthma exacerbation with SMART, compared to same-dose inhaled corticosteroid alone (11% lower risk of asthma exacerbation when compared to higher dose inhaled corticosteroids alone) 6.3% lower risk of asthma exacerbation with SMART, compared to the same dose of inhaled corticosteroid combined with a long-acting beta-agonist (2.7% lower risk of asthma exacerbation when compared to higher dose inhaled corticosteroid combined with a long-acting beta-agonist) Harms in NNT (NNH) Harms were not assessed Harms in percentages Harms were not assessed Efficacy endpoints Asthma exacerbations defined as requiring systemic use of corticosteroids, hospitalization, ED visits, intensive care admission, or intubation Harm endpoints Harms were not assessed Who was in the studies 22,748 patients (aged ≥ 5 years) with persistent asthma, already receiving inhaled corticosteroids from 16 randomized clinical trials